These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 28746779)
1. Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD. Nobili V; Alisi A; Mosca A; Della Corte C; Veraldi S; De Vito R; De Stefanis C; D'Oria V; Jahnel J; Zohrer E; Scorletti E; Byrne CD Liver Int; 2018 Feb; 38(2):342-349. PubMed ID: 28746779 [TBL] [Abstract][Full Text] [Related]
2. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH. Hernandez GV; Smith VA; Melnyk M; Burd MA; Sprayberry KA; Edwards MS; Peterson DG; Bennet DC; Fanter RK; Columbus DA; Steibel JP; Glanz H; Immoos C; Rice MS; Santiago-Rodriguez TM; Blank J; VanderKelen JJ; Kitts CL; Piccolo BD; La Frano MR; Burrin DG; Maj M; Manjarin R Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G582-G609. PubMed ID: 32003601 [TBL] [Abstract][Full Text] [Related]
3. The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease. Aguilar-Olivos NE; Carrillo-Córdova D; Oria-Hernández J; Sánchez-Valle V; Ponciano-Rodríguez G; Ramírez-Jaramillo M; Chablé-Montero F; Chávez-Tapia NC; Uribe M; Méndez-Sánchez N Ann Hepatol; 2015; 14(4):487-93. PubMed ID: 26019035 [TBL] [Abstract][Full Text] [Related]
4. Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study. Appleby RN; Moghul I; Khan S; Yee M; Manousou P; Neal TD; Walters JRF PLoS One; 2019; 14(1):e0211348. PubMed ID: 30682184 [TBL] [Abstract][Full Text] [Related]
5. Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease. Alisi A; Ceccarelli S; Panera N; Prono F; Petrini S; De Stefanis C; Pezzullo M; Tozzi A; Villani A; Bedogni G; Nobili V PLoS One; 2013; 8(6):e67160. PubMed ID: 23840612 [TBL] [Abstract][Full Text] [Related]
6. Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis. Schumacher JD; Guo GL Handb Exp Pharmacol; 2019; 256():325-357. PubMed ID: 31201553 [TBL] [Abstract][Full Text] [Related]
7. Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial. Friedrich D; Marschall HU; Lammert F BMC Gastroenterol; 2018 Jun; 18(1):76. PubMed ID: 29866129 [TBL] [Abstract][Full Text] [Related]
8. INT-767 improves histopathological features in a diet-induced Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205 [TBL] [Abstract][Full Text] [Related]
9. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Jiao N; Baker SS; Chapa-Rodriguez A; Liu W; Nugent CA; Tsompana M; Mastrandrea L; Buck MJ; Baker RD; Genco RJ; Zhu R; Zhu L Gut; 2018 Oct; 67(10):1881-1891. PubMed ID: 28774887 [TBL] [Abstract][Full Text] [Related]
10. Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents. Mosca A; Nobili V; De Vito R; Crudele A; Scorletti E; Villani A; Alisi A; Byrne CD J Hepatol; 2017 May; 66(5):1031-1036. PubMed ID: 28214020 [TBL] [Abstract][Full Text] [Related]
11. An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers. Al-Khaifi A; Rudling M; Angelin B Gastroenterology; 2018 Oct; 155(4):1012-1016. PubMed ID: 29928896 [TBL] [Abstract][Full Text] [Related]
12. Dynamics of Bile Acid Profiles, GLP-1, and FGF19 After Laparoscopic Gastric Banding. Thöni V; Pfister A; Melmer A; Enrich B; Salzmann K; Kaser S; Lamina C; Ebenbichler CF; Hackl H; Tilg H; Moschen AR J Clin Endocrinol Metab; 2017 Aug; 102(8):2974-2984. PubMed ID: 28591793 [TBL] [Abstract][Full Text] [Related]
13. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH). Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182 [TBL] [Abstract][Full Text] [Related]
14. Dynamic pattern of postprandial bile acids in paediatric non-alcoholic fatty liver disease. Huang J; Lin H; Liu AN; Wu W; Alisi A; Loomba R; Xu C; Xiang W; Shao J; Dong G; Zheng MH; Fu J; Ni Y Liver Int; 2024 Oct; 44(10):2793-2806. PubMed ID: 39082260 [TBL] [Abstract][Full Text] [Related]
15. Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression. Nimer N; Choucair I; Wang Z; Nemet I; Li L; Gukasyan J; Weeks TL; Alkhouri N; Zein N; Tang WHW; Fischbach MA; Brown JM; Allayee H; Dasarathy S; Gogonea V; Hazen SL Metabolism; 2021 Mar; 116():154457. PubMed ID: 33275980 [TBL] [Abstract][Full Text] [Related]
16. Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease. Wunsch E; Milkiewicz M; Wasik U; Trottier J; Kempińska-Podhorodecka A; Elias E; Barbier O; Milkiewicz P Sci Rep; 2015 Aug; 5():13462. PubMed ID: 26293907 [TBL] [Abstract][Full Text] [Related]
17. Obeticholic acid may increase the risk of gallstone formation in susceptible patients. Al-Dury S; Wahlström A; Panzitt K; Thorell A; Ståhlman M; Trauner M; Fickert P; Bäckhed F; Fändriks L; Wagner M; Marschall HU J Hepatol; 2019 Nov; 71(5):986-991. PubMed ID: 31254596 [TBL] [Abstract][Full Text] [Related]
18. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Bechmann LP; Kocabayoglu P; Sowa JP; Sydor S; Best J; Schlattjan M; Beilfuss A; Schmitt J; Hannivoort RA; Kilicarslan A; Rust C; Berr F; Tschopp O; Gerken G; Friedman SL; Geier A; Canbay A Hepatology; 2013 Apr; 57(4):1394-406. PubMed ID: 23299969 [TBL] [Abstract][Full Text] [Related]
19. Bile Acids and the Gut Microbiome as Potential Targets for NAFLD Treatment. Zhu L; Baker RD; Zhu R; Baker SS J Pediatr Gastroenterol Nutr; 2018 Jul; 67(1):3-5. PubMed ID: 29697548 [TBL] [Abstract][Full Text] [Related]
20. FXR-FGF19 signaling in the gut-liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence. Simbrunner B; Hofer BS; Schwabl P; Zinober K; Petrenko O; Fuchs C; Semmler G; Marculescu R; Mandorfer M; Datz C; Trauner M; Reiberger T Hepatol Int; 2024 Jun; 18(3):929-942. PubMed ID: 38332428 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]